Oncology is among the most active therapeutic fields in terms of new drug development projects, with increasingly expensive drugs. The expected clinical benefit and cost effectiveness of these treatments in clinical practice have yet to be fully confirmed. Health medico-administrative databases may be useful for assessing the value of anticancer drugs with real-world data.
The objectives of our systematic literature review (SLR) were to analyse economic evaluations of anticancer drugs based on health medico-administrative databases, to assess the quality of these evaluations, and to identify the inputs from such databases that can be used in economic evaluations of anticancer drugs.
We performed an SLR by using PubMed and Web of Science articles published from January 2008 to January 2019. The search strategy focused on anticancer drug cost-effectiveness analyses (CEAs)/cost-utility analyses (CUAs) that were entirely based on medico-administrative databases. The review reported the main choices of economic evaluation methods in the analyses. The quality of the articles was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and risk of bias assessment checklists.
Of the 306 records identified in PubMed, 12 articles were selected, and one additional article was identified through Web of Science. Ten of the 13 articles were CEAs and three were CUAs. Most of the analyses were carried out in North America (n = 11). The economic metric used was the cost per life-year gained (n = 10) or cost per quality-adjusted life-year (n = 3). Reporting of the target analysis population and strategies in the articles was in agreement with the CHEERS guidelines. The structural assumptions underpinning the economic models displayed the poorest reporting quality among the items analysed. Representativeness bias (n = 11) and the issue of censored medical costs (n = 8) were the most frequently analysed risks.
A comparison of the economic results was not relevant due to the high heterogeneity of the selected studies. Our SLR highlighted the benefits and pitfalls related to the use of medico-administrative databases in the economic evaluations of anticancer drugs.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Paris V. Cost of anticancer drugs: a challenge for health systems of OCDE countries. Bull Acad Natle Méd. 2019;202(5–6):989–1002.
Institut National du Cancer. Les cancers en France en 2018: l’essentiel des faits et des chiffres. Edition 2019. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Les-cancers-en-France-en-2018-L-essentiel-des-faits-et-chiffres-edition-2019. Accessed 04 Jun 2019.
Howard D, Bach P, Berndt E, Conti R. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.
Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, et al. EMA and NICE appraisal processes for cancer drugs: current status and uncertainties. Appl Health Econ Health Policy. 2018;16(4):429–32.
Megerlin F. Médicaments innovants onéreux: vers le paiement de résultats contractualisés? Revue Française des affaires sociales. 2018;3:129–46.
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drugs approvals 2009–2013. BMJ. 2017;359:4530–42.
OECD. Using routinely collected data to inform pharmaceutical policies: Analytical Report for OECD and EU Countries. 2019. http://www.oecd.org/els/health-systems/routinely-collected-data-to-inform-pharmaceutical-policies.htm. Accessed 04 Jun 2019.
Abecassis P, Coutinet N. Economie du médicament. La découverte: Collection REPERES; 2018.
Mues K, Liede A, Liu J, Wetmore J, Zaha R, Bradbury B, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–77.
Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Revue d’Épidémiologie et de Santé Publique. 2017;65(Suppl 4):S149–67.
Haute Autorité de Santé. Guide méthodologique—Choix méthodologiques pour l’évaluation économique à la HAS. 2011. https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf. Accessed 04 Jun 2019.
Belgian Guidelines for economic evaluations and budget impact analysis. KCE. 2015. https://kce.fgov.be/sites/default/files/page_documents/KCE_183_economic_evaluations_second_edition_Report.pdf. Accessed 04 Jun 2019.
Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0). Australian Government Department of Health. 2016. http://www.pbac.pbs.gov.au/content/information/printable-files/pbacg-book.pdf. Accessed 04 Jun 2019.
National Institute for Health and Care Excellence (NICE). Single technology appraisal: user guide for company evidence submission template. 2015. https://www.nice.org.uk/process/pmg24/chapter/cost-effectiveness. Accessed 04 Jun 2019.
Martin-Latry K, Cougnard A. Terminology used in publications of pharmacoepidemiological research in France using health insurance reimbursement databases: need for harmonization. Therapie. 2010;65(4):379–85.
Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–62.
Moher D, Liberati A, Tetzlaff J, Altman D; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
Liberati A, Altman D, Tetzlaff J, Mulrow C, Getzsche P, Ioannidis J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
Rovithis D. Do health economic evaluations using observational data provide reliable assessment of treatment effects? Health Econ Rev. 2013;3:21.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. On behalf of the ISPOR Health Economic Evaluation Publication Guidelines—CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–50.
Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1(1):35–47.
Bang H, Tsiatis A. Median regression with censored cost data. Biometrics. 2002;58:643–9.
Faria R, Alava MH, Manca A, Wailoo AJ. NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data, May 2015. Decision Support Unit, ScHARR? University of Sheffield. 2015. http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2016/03/TSD17-DSU-Observational-data-FINAL.pdf. Accessed 04 Jun 2019.
Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value Health. 2017;20(8):1003–8.
Mack C, Su Z, Mendelsohn A, Dreyer N. Prevention, examination and treatment of missing data in nonexperimental pharmacoepidemiologic studies. Chin J Pharmacoepidemiol. 2015;24(1):14–22.
US FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data, Guidance for Industry and FDA Staff. 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm243537.pdf. Accessed 04 Jun 2019.
PCORI. Data Quality and Missing Data in Patient Centered Outcomes Research Using EMR/Claims Data Meeting Summary. 2015. http://www.pcori.org/sites/default/files/PCORI-Data-Quality-and-Missing-Data-Workgroup-Summary-121015.pdf. Accessed 04 Jun 2019.
National Academy of Sciences. The Prevention and Treatment of Missing Data in ClinicalTrials. Panel on Handling Missing Data in Clinical Trials, National Research Council. Washington, DC: National Academies Press; 2010.
Mendelsohn A, Dryer N, Mattox P, Su Z, et al. Characterization of missing data in clinical registry studies. Ther Innovation Regul Sci. 2015;49:146–54.
Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, et al. Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014;14:586.
Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, et al. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia. Eur J Cancer. 2012;48:1969–76.
Shih YC, Pan IW, Tsai YW. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009;27(11):947–61.
Shin S, Park CM, Kwon H, Lee KH. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer. 2016;16:443.
Chen Y, Lairson DR, Chan W, Huo J, Du XL. Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a US Payer’s perspective. J Manag Care Spec Pharm. 2017;23(8):831–43.
Gilden DM, Kubisiak JM, Pohl GM, Ball DE, Gilden DE, John WJ, et al. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017;20(2):151–61.
Woldemichael A, Onukwugha E, Seal B, Hanna N, Mullins CD. Sequential therapies and the cost-effectiveness of treating metastatic colon cancer patients. J Manag Care Spec Pharm. 2016;22(6):628–39.
Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics. 2014;32(1):63–74.
Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012; 978391.
Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118(24):6079–88.
Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL. Cost-effectiveness of chemotherapy for breast cancer and age effect in older women. Value Health. 2015;18(8):1070–8.
Lairson DR, Parikh RC, Cormier JN, Du XL. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health. 2014;17(1):34–42.
Howard D, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med. 2010;170(6):537–42.
Tuppin P, Pestel L, Samson S, Cuerq A, Rivière S, Tala S, et al. The human and economic burden of cancer in France in 2014, based on the Sniiram national database in French]. Bull Cancer. 2017;104(6):524–37.
Baudot FO, Aguadé AS, Barnay T, Gastaldi-Ménager C, Fagot-Campagna A. Impact of type 2 diabetes on health expenditure: estimation based on individual administrative data. Eur J Health Econ. 2019. https://doi.org/10.1007/s10198-018-1024-9.
Gansen F. Health economic evaluations based on routine data in Germany: a systematic review. BMC Health Serv Res. 2018;18:268.
National Cancer Institute. Comprehensive cancer information. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed 07 Jan 2019.
Kreif N, Grieve R, Sadique MZ. Statistical methods for cost-effectiveness analyses that use observational data: a critical appraisal tool and review of current practice. Health Econ. 2013;22(4):486–500.
Bell H, Wailoo A, Hernandez M, Grieve R, Faria R, Gibson L, et al. The use of real world data for the estimation of treatment effects in NICE decision making. 2016. http://nicedsu.org.uk/wp-content/uploads/2018/05/RWD-DSU-REPORT-Updated-DECEMBER-2016.pdf. Accessed 04 Jun 2019.
Hampson G, Towse A, Dreitlein WB, Henshall C, Pearson SD. Real-world evidence for coverage decisions: opportunities and challenges. J Comp Eff Res. 2018;7(12):1133–43.
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 4). EMA/95098/2010. 2010. http://www.encepp.eu/standards_and_guidances. Accessed 04 Jun 2019.
Ghabri S, Stevenson M, Möller J, Caro J. Trusting the results of model-based economic analyses: is there a pragmatic validation solution? Pharmacoeconomics. 2019;37:1–6.
Légifrance LOI n° 2016-41 du 26 janvier 2016 de modernisation de notre système de santé (1). 2016. https://www.legifrance.gouv.fr/eli/loi/2016/1/26/AFSX1418355L/jo/texte/fr#JORFSCTA000031912698. Accessed 04 Jun 2019.
Bousquet PJ, Lefeuvre D, Tuppin P, BenDiane MK, Rocchi M, Bouée-Benhamiche E, et al. Cancer care and public health policy evaluations in France: usefulness of the national cancer cohort. PLoS One. 2018;13(10):e0206448.
The authors would like to thank the anonymous reviewers and the Editor-in-Chief for their careful reading of the manuscript and insightful comments and suggestions. They would also like to thank Meryl Darlington, Lionel Perrier and Dominic Thorrington for their valuable comments on earlier drafts of the manuscript. The opinions expressed in this article are those of the authors and do not necessarily represent the views of their affiliated institutions.
Conflict of interest
Elsa Bouée-Benhamiche, Philippe Jean Bousquet and Salah Ghabri have no conflicts of interest to declare. Salah Ghabri is employed by HAS, and Elsa Bouée-Benhamiche and Philippe Jean Bousquet are employed by INCa.
This study was not funded by any specific project grants.
Data Availability Statement
Any data valid at the time of the current review are presented in the ESM.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Bouée-Benhamiche, E., Bousquet, P.J. & Ghabri, S. Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review. Appl Health Econ Health Policy 18, 491–508 (2020). https://doi.org/10.1007/s40258-020-00562-z